Stay updated on Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The page has removed a reference to a study on the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer, which may impact the credibility and informational value of the content related to cancer treatments.
    Difference
    0.6%
    Check dated 2025-05-07T20:34:55.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.15.0 to v2.15.2 and added a reference to a randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in non-small-cell lung cancer.
    Difference
    0.9%
    Check dated 2025-04-30T18:43:13.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The page has added information regarding Pembrolizumab as a treatment for non-small-cell lung cancer, along with references to relevant medical literature.
    Difference
    1%
    Check dated 2025-04-23T15:52:39.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect a new study on Stage IIIA Non-small Cell Lung Cancer, specifically focusing on the use of Cisplatin and Paclitaxel, while removing details about a previous study involving pembrolizumab. The revision number has also been updated.
    Difference
    47%
    Check dated 2025-04-16T13:13:24.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated to include new information regarding the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer, and the version has been revised from v2.14.3 to v2.14.4.
    Difference
    0.7%
    Check dated 2025-04-09T05:56:01.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has removed a reference to a study on the safety and activity of an anti-PD-L1 antibody in patients with advanced cancer.
    Difference
    0.6%
    Check dated 2025-04-01T22:53:05.000Z thumbnail image

Stay in the know with updates to Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Adjuvant Pembrolizumab in N2+ NSCLC Clinical Trial page.